Pharmaceutical Research
Maximum tolerated dose of PKI166 in patients with advanced solid malignancies determined
Published in Cancer Weekly, December 13th, 2005
"This phase I study was conducted to assess the tolerability, pharmacokinetics, and antitumor activity of the oral, selective epidermal growth factor receptor tyrosine kinase inhibitor PKI166 in patients with advanced solid malignancies. Experimental PKI166 was first given once daily continuously and in the second part of the study once daily for 2 weeks every 4 weeks to establish the MTD," researchers in the Netherlands reported.
"Ten additional patients were studied at MTD to acquire additional safety information and characterize the effect of...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2005-12-13)
More Articles from Cancer Weekly
- Cancer Risk Factors
Night work might be related to breast cancer risk - Cancer Therapy
Interferon treatment increases virotherapy for advanced hepatocellular carcinoma - Healthcare Costs
Taxane test-dose reduced cost associated with hypersensitivity reaction - Anemia
First long-term phase II study of CERA in renal patients shows control of anemia - Apoptosis
2-cyano-3,12-dioxooleana-1,9-dien-28-imidazolide (CDDO-Im) induced apoptosis in pancreatic cancer - Apoptosis
Biological stimuli of neuroblastoma cell response analyzed - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
